

CARBAZOLE: AN UPDATED PROFILE OF BIOLOGICAL ACTIVITIES

Babita Rawat¹, Sucheta¹, Shivali Rahi² and Arpana Rana^{2*}

¹K.R. Mangalam University, Sohna Road, Gurgaon, Haryana-122 103, India.

²Advanced Institute of Pharmacy, 70 km Delhi-Mathura Road,
Palwal, Haryana-121 105, India.

ABSTRACT

Past several years report the significance of the heterocyclic nucleus carbazole and its derivatives. Carbazole skeleton is key pharmacophore for many biologically active compounds in synthetic as well as natural. The present review compiles biological profile of carbazole and its derivatives from 2012 till now.

Keywords: Carbazole, biological activity, anticancer, antibacterial and antiproliferative.

INTRODUCTION

Heterocyclic chemistry acted as a boon in drug discovery and there are many pharmacologically active heterocyclic compounds. Out of which nitrogen containing heterocyclic compounds remained the favorite of researchers.

Carbazoles are nitrogen containing aromatic heterocyclic compounds¹. Structure of carbazoles possess desirable electronic and charge transport properties as well as large π -conjugate system and the various functional groups that can be easily introduced into the structurally rigid carbazolyl ring²⁻⁴.

Presence of particular characteristics in the structure are responsible for potential applications of carbazole and its derivatives in the field of chemistry including photoelectrical materials, dyes etc⁵.

Carbazole skeleton (1)⁶ is the key element for many biological active compounds including synthetic and natural products for example carbazomycins, class of antibiotics have carbazole framework carbazomycin A and B inhibits growth of phytopathogenic fungi and have antibacterial and anti-yeast activities⁷⁻¹⁰. other major example is of carbazole alkaloids naturally occurring heterocycles with carbazole skeleton isolated from the Rutaceae family, which has properties like stimulant, stomachic, febrifuge, analgesic also used in the treatment

of diarrhea, dysentery, insect bites and show antibacterial activity¹⁰⁻¹².

Many other derivatives of alkaloids such as ellipticine and 9-methylelpticine has anticancer activities¹³. Synthetic carbazoles and its derivatives has supramolecular recognition show pharmacological activities like antitumor¹⁴, antimicrobial, anticonvulsants¹⁵, antihistaminic, antioxidative, anti-inflammatory, antidiabetic, psychotropic, antiproliferative etc.¹⁶⁻²⁰. Keeping in mind the vast therapeutic potential of carbazole, the present review focuses on the recent progress, from 2012 till now, in knowledge on various biological activities of carbazole and its derivatives.

Anti-Alzheimer

Choubdar N, et al., (2019)²¹ has synthesized a series of compounds comprising the carbazole backbone linked to the benzyl piperazine, benzyl piperidine, pyridine, quinoline, isoquinolinemoiety through an aliphatic linker and evaluated as cholinesterase inhibitors. The synthesized compound (2) showed IC₅₀ values of 0.11-36.5 μ M and 0.02-98.6 μ M against acetyl and butyrylcholinesterase (AChE and BuChE), respectively. The ligand-protein docking stimulations and kinetic studies revealed that compound (2) could bind effectively to the peripheral anionic binding site

(PAS) and anionic site of the enzyme with mixed-type inhibition. Compound (2) was the most potent compound against AChE and BuChE and showed acceptable inhibition potency for self and AChE-induced A β 1-42 aggregation. Moreover, compounds (2) could significantly protect PC12 cell against H₂O₂-induced toxicity. The results suggested that the compounds (2) could be considered as a promising multi-functional agent for further drug discovery development against Alzheimer's disease.

Ghobadian R., et al., (2018)²² have synthesized and designed a new series of carbazole-Benzyl Pyridine derivatives and evaluated as butyrylcholinesterase (BChE) inhibitors. In vitro assay revealed that all of the derivatives has selective and potent anti-BChE. 3-((9H-carbazole-9-yl)methyl)-1-(4-chlorobenzyl)pyridine-1-ium chloride compound (3) had the most potent anti-BChE activity (IC₅₀ value=0.073 μ M), the highest BChE selectivity and mixed-type inhibition. Docking study revealed that compound (3) interacted with the peripheral site, the choline binding site, catalytic site and the acyl pocket of BChE. Physicochemical properties were accurate to lipinski's rule. In addition, compound (3) demonstrated neuroprotective activity at 10 μ M. this compound can also inhibit AChE-induced and self-induced A β peptide aggregation at concentration of 100 μ M and 10 μ M respectively. The *in-vivo* study showed that compound (3) in 10mg/kg increased the time spent in target quadrant in the probe day and decreased mean training period scape latency in rats. All results suggest that new sets of potent selective inhibitors of AChE have a therapeutic potential for the treatment of AD.

Antibacterial activity

Dabrovolksas K., et al (2020)²³ has synthesized several compounds 3-cyano-9H-carbazole (4), 3-iodo-9H-carbazole (5) and 3,6-Dibromo-9H-carbazole (6) by known methods, and their antibacterial activity was evaluated against *Bacillus subtilis* and *Escherichia coli* using a disk diffusion method. The disk diffusion method revealed that tested compounds showed antibacterial activity against tested strains, they inhibited the growth of bacteria at various concentration, from 31.25 to 250 μ g/ml. 3-cyano-9H-carbazole, 3-iodo-9H-carbazole and 3,6-Dibromo-9H-carbazole showed a stronger antibacterial activity against *Bacillus subtilis* compared to the reference drug amoxicilline. Whereas, 1,3,6-Tribromo-9-H-carbazole (7) showed a stronger activity against *Escherichia coli*.

Venktapathy K., et al (2020)²⁴ have been design and the eco-benign synthesis of new class of carbazolyl-1,4-dihydropyridine (1,4-CDHP) (8) and carbazolyl-1,-8-dioxodecahydroacridine (9) (CAD) derivatives via a three-component coupling reaction of substituted carbazole aldehydes, ethyl acetoacetate/dimedone, and ammonium acetate under solvent-free conditions at 112 °C to 115 °C. they also reports an efficient one pot synthesis of new class of carbazolylpolyhydroquinoline (CPQ) derivatives via a four-component coupling reaction of substituted ethyl acetoacetate, dimedone, ammonium acetate, and carbazole aldehydes in acetonitrile/water medium (3:1) at 73 °C to 75 °C in moderate yields. The synthesized heterocyclic compound (8 and 9) showed antibacterial activity against pathogenic strains of both Gram-negative and Gram-positive bacteria. Minimum inhibitory concentration (MIC) of the active compounds was evaluated by macrodilution method.

Guhanathan S., et al (2019)²⁵ has synthesized bromoderivative N-bromoacetyl-5,8-dibromo 5,6-dihydro(3,2-a) (10) and N-bromoacetyl-2,6-dibromo-1,2,3,4-tetrahydrocarbazole (11) of carbazole compounds by free radical bromination using 4-bromophenylhydrazine and various reactant such as alpha-tetralone cyclohexanone and cyclopentanone with suitable solvent such as carbontetrachloride. The solvent selected must be suitable for reaction condition and temperature. Brominated carbazole derivatives(10) and (11) were further acetylated using bromoacetyl bromide in DMF as a solvent. The synthesized compound (10) & (11) found to have excellent antibacterial activity.

Pattanashetty S.H., et al (2018)²⁶ has synthesized N-phenylacetamide-functionalized (12a-j) derivatives under conventional method in excellent yields. N-substituted carbazole exhibited potent antibacterial activity against *S. aureus*, *B. subtilis*, *E. coli*, *P. aeruginosa*. Among all tested compound (12a), (12e), (12g) and (12h) exhibited antibacterial activity with MICs ranging from 2.0 to 0.25 μ g/ml

Wang pei-yi, et al., (2017)²⁷ has synthesized various pyridinium-functionalized carbazole derivatives that were constructed by coupling the key fragments of carbazole skeleton and pyridinium nucleus in a single molecular architecture. Antibacterial bioassays revealed that some of the title compounds displayed impressive bioactivities against plant pathogens such as *Xanthomonas oryzae* sp., *Oryzae, ralstolniasolanacearum*, and *Xanthomonas axonopodis* sp. *Citri* with minimal EC₅₀ values of up to 0.4, 0.3, and 0.3mg /L, respectively. These bioactivities were achieved

by systematically tuning and optimizing bridging linker, alkyl length of the tail, and substituents on the carbazole scaffold. Compared with the bioactivity of the lead compound (13), antibacterial efficacy dramatically increased by approximately 13-, 104- and 21- fold. This finding suggested that these compounds can serve as new lead compound (13) in research on antibacterial chemotherapy.

Parthiban P, et al.,(2014)²⁸ has designed and synthesized a series of N-((5,6,7,8-tetrahydro carbazol-9-yl-methyl) substituted amines (14,15) and evaluation as a antibacterial activity against *E. coli*, *P.aeruginosa*, *K. pneumonia*, *S. typhii*, *Staphylococcus aureus*, amoxicillin used as standard drug and antifungal activity against *C. Albicans* and *A. Niger* at 50 and 100µg/ml level.

Griseofulvin (50 and 100µg/ml) act as antifungal activity *C. Albicans* and *A. Niger*. According to this compound (14,15) showed better antifungal activity against 100µg/ml concentration, all the compounds showed will antifungal activity compound moderate activity against *S. Aureus* and exhibited more activity all bacteria.

Sharma D., et al (2014)²⁹ was designed a novel series 5-[(9*H*-carbazol-9-yl)methyl]-*N*-[substituted phenyl](piperazin-1-yl)methyl]-1,3,4-Oxadiazol-2-amines (16a-o) derivatives was synthesized by starting with carbazole, which on reaction with ethyl chloroacetate yielded ethyl 2-(9*H*-carbazole-9-yl)acetate. All the derivatives were evaluated for their antibacterial activity. Compound 16a, 16d, 16e, 16n showed antibacterial activity.

Kaushik K., et al (2012)³⁰ synthesized a series of carbazole on reaction with chloroacetyl chloride afforded *N*⁹-(chloroacetyl)-carbazole (17) which on treatment with hydrazine hydrate has yielded *N*⁹-(hydrazinocetyl)-carbazole, condensation with various aromatic aldehydes afforded *N*⁹(arylidenehydrazinoacetyl)-carbazoles, which on cycloaddition with isatin in the presence of ammonium acetate yielded 1-carbazole-9-yl-2-(substitutedphenyl)-1,4-dihydroimidazo-[4,5-b]indol 1-yl-amino)-ethanone (17a-k). All the synthesized compound were evaluated for their antibacterial activity. Compound were screened for in-vitro antibacterial activity against the two-gram positive bacterial strains like *staphylococcus aureus* and *bacillus subtilis* and two-gram negative bacterial strain like *Pseudomonas aeruginosa* and *Escherichia coli*. All the newly synthesized compound (17d) and (17e) showed most potent antibacterial activity against all bacterial strain.

Anticancer activity

Liu Y., et al (2020)³¹ was formulated and investigated the structure-activity relationship of novel *N*-substituted carbazole sulfonamide derivatives with improved physicochemical properties. Most of these new compounds displayed good aqueous solubility. Certain molecules presented strong *in vitro* antiproliferative and *in vivo* antitumor activity. Relative to the control, 50 mg/kg compound (18) reduced human HepG2 xenograft mouse tumor growth by 54.5% and its efficacy was comparable to that of CA-4P. They also developed a novel synthetic method for 7-hydroxy-substituted carbazole sulfonamides. Compared with the control, 25 mg/kg compound (18) inhibited human HepG2 xenograft mouse tumor growth by 71.7% and was more potent than 50 mg/kg CA-4P with only 50% tumor shrinkage efficacy. Among the three water-soluble carbazole sulfonamide derivatives formulated in the present study. Compound (18) displayed the most effective tumor growth inhibition *in vivo* and merit further investigation as potential antitumor agent cancer therapy.

Rao Durga B.V., et al (2019)³² has synthesized a series of isoxazole-thiadiazole linked carbazole derivatives (19a-j). The products are tested for their anticancer activity against human cancer cell line: MCF-7 (breast), A549 (lungs), DU-145 (prostate), and MDA MB-231 (breast) by using MTT assay and etoposide as a reference drug. The accumulated data indicate that most of the compound 19b, 19c, 19d, 19f, 19g exhibited very strong anticancer activity.

Jiang H., Zhang W.J., et. al (2018)³³ has synthesized a series of carbazole-rhodanine conjugates and evaluated for their topoisomerase II inhibition potency as well as cytotoxicity against a panel of four human cancer cell lines. Among, these compounds, 20a, 20b, 20g, possessed topoisomerase II inhibition potency at 20µg. Mechanism study revealed that these compounds may function as topo II catalytic inhibitors. It was found that the electron withdrawing groups on the phenyl ring of compound (20a) played an important role on enhancing both enzyme inhibition and cytotoxicity.

Vlaar C.P., et al (2018)³⁴ has been synthesized a new series of carbazole derivatives. Based on the efficacy of EHOp-016 as an inhibitor of migration and Rac1 activation. Cytotoxic and anti-migratory effects of these compounds were evaluated in MCF-7 and MDA-MB-231 breast cancer cell lines. Preliminary investigation of their anticancer demonstrated that several compounds have moderate antiproliferative effects on cancer cell lines

with GI_{50} values in the range of 13-50 μ M. Furthermore, compounds (21, 22) inhibit migration activity of metastatic cell line MDA-MtB-231 by 32% and 34%, respectively. Compound (22) was shown to inhibit activation of the Rho GTPase Rac1 by 55% at 250nMin both MDA-MB-231 and MDA-MB-435 cell lines. Compared with the IC_{50} of Rac1 inhibition by lead compound EHop-016 of 1.1 μ M, compound (12) demonstrates 4X improved *in vitro* efficacy.

You X., et al (2018)³⁵ synthesized a set of structurally diverse synthetic carbazoles was screened for their anticancer activities. According to structure-activity relationship studies, carbazoles with an N-substituted sulfonyl group exhibited better anticancer activity. Moreover, compound (23) was discovered to show the most potent anticancer effects on capan-2 cells by inducing apoptosis and cell cycle arrest in G2/M phase. Finally, the *in vivo* study demonstrated that (23) prevented that the tumor growth in PANC-1 and capan-2 xenograft models without apparent toxicity.

Kumar N., et al (2016)³⁶ have designed series of such active compounds i.e. 2-[(4,5-dihydro-2-substituted phenyl)imidazole-1-ylamino]-1-(9H-carbazole-9-yl) ethanone and 2-(9H-carbazole-9-yl)-N-[(4-substituted phenyl)(piperazine-1-yl)methyl]acetohydrazide were synthesized. All the synthesized compounds were screened for their *in vitro* anticancer activity against human breast cancer cell line (MCF 7) by sulphorodamine B (SRB) assay method. GI_{50} was majored by using 10, 20, 40 and 80 μ g/ml concentration of tested compound along with the standard i.e. Adriamycine. Result revealed that the tested compound was comparable to Adriamycine having GI_{50} <10 μ g/ml. compound (24, 25) was found to be most active among all the tested compounds. Carbazole in combination with other heterocycles might be used as a lead for finding of the potent anticancer agents. Substitution at 9th position also increases the therapeutic value of carbazole toward the treatment of cancer.

Li. B., et al., (2013)³⁷ has synthesized a series of pyrido[3,2- α] carbazole derivatives and all these compounds evaluated for their antitumor activity against human lung cancer A549 cells and colon cancer HT29 cells. The intermediates are successfully synthesized and ethyl 2-(3-bromopyridine-2-yl) acetate by Knoevenagel condensation intramolecular heck-type reaction and this is a novel efficient synthetic approach to the core scaffold of the target compounds. These target compounds have shown an interesting antitumor profile towards the tested cell lines with IC_{50} values

ranging from 0.007 μ M to 4.45 μ M. Among all the compounds synthesized, compound (26, 27) showed higher potency.

Gu. W., et al (2014)³⁸ had designed and synthesized a series of new carbazole derivatives of ursolic acid. All the synthesized compounds were evaluated for anti-cytotoxic activity. *In vitro* cytotoxicity of these compounds is assayed against two human tumor cell lines (SMMC-7721) and HepG2 using MTT colorimetric method. Among all these compounds (28e) was found to be the most potent compound with IC_{50} values of 1.08 \pm 0.22 and 1.26 \pm 0.17 μ M against SMMC-7721 and HepG2 cells, respectively, comparable to those of doxorubicin. In addition, compound (28) showed reduced cytotoxicity against noncancerous LO2 cells with IC_{50} value of 5.75 \pm 0.48 μ M.

Haider. N., et al (2014)³⁹ has synthesized new b-Fused carbazoles N'-(9-bromo-1-chloro-5-methyl-6H-pyridazino[4,5-b]carbazole-4-yl)-N,N-diethylpropane-1,3-diamine(29) and 8-Bromo-2-[3-(diethylamino)propyl]-4-methylpyrrolo[3,4-b]carbazole-1,3(2H,5H)-dione(30). Interestingly, the two compounds showed marked differences in cell-type specially, with 30 being most active against HTB65 and (29) against the SW480 line.

Howorko. J.R., et al (2013)⁴⁰ has synthesized 1-substituted pyrido[4,3-b]carbazole derivative. All of them were tested *in vitro* for their anticancer activity on three tumor cell lines: CCRF/CEM(T lymphoblast leukemia), A549 (lung adenocarcinoma), and MCF7 (breast cancer). Among all compounds, compound (31, 32, 33) were showed strongest anticancer activity.

Kalplancikli. Z.A., et al (2012)⁴¹ had synthesized some N-(9-Ethyl-9-H-carbazole-3-yl)-2-(phenoxy)acetamide derivatives for their anticytotoxic activity. The title compounds were obtained by reacting 2-chloro-N-(9-ethyl-9H-carbazole-3-yl) acetamide with some substituted phenols. All the synthesized compound (34) was studied for their cytotoxic effects MTT assay, and it was seen that (34) had the lowest cytotoxic activity against NIH/3T3 cells.

Anti-inflammatory activity

Muniyappan. G., et al (2016)⁴² was synthesized a novel 4-hydroxycarbazole derivatives. The reaction involved O-alkylation of 4-hydroxycarbazole using methyl 5-bromovalerate. All the synthesized compounds were screened for their *in vitro* anti-inflammatory activity. Among the synthesized compounds, compound (35a, 35b and 35c) were found to show good anti-inflammatory

activities against the standard drug diclofenac sodium.

Surendiran. T., (2015)⁴³ has synthesized the compounds isoxazolonyl and pyrazolonyl-1,2,3,4-tetrahydrocarbazoles were individually prepared by using chalconyl-1,2,3,4-tetrahydrocarbazoles (36, 37) with condensation of hydroxylamine hydrate and hydrazine hydrate respectively. All titled compounds were evaluated against anti-inflammatory activities by using carrageenan induced edema model in rats.

Bandgar.B.P., et al (2012)⁴⁴ has synthesized a novel series of 3-(substituted)-aryl-5-(9-methyl-3-carbazole)-1*H*-2-pyrazolines(38a-o). All the synthesized compounds were evaluated for their *in vitro* and *in vivo* anti-inflammatory activity. Compound (38c) was found to potent inhibitor of the carrageenin induced paw edema in rats. Molecular docking result, along with the biological assay data, suggested that compound (38c) was a potential anti-inflammatory agent.

Antimicrobial activity

Jasass R.S., et al (2018)⁴⁵ has synthesized new derivatives of carbazole incorporated with thiazole moiety via the reaction of carbazole thiosemicarbazone with hydrazonoyl chloride under microwave irradiation. The spectral results and the absorption data proved the postulated structures of the resulting compounds. The starting thiosemicarbazone and compound (39) and (40) were evaluated against two fungi G⁺ bacteria and G⁻ bacteria. The results obtained explore the high potency of some of the tested compounds compared with the employed standard bactericides and fungicides.

Chakraborty S., et al (2017)⁴⁶ has been synthesized 6-fluoro-1*H*-carbazole(41), 6-fluoro-2-methyl-1*H*-carbazole(42), 6-fluoro-3-methyl-1*H*-carbazole(43) and their respective quinone derivatives 6-fluoro-1*H*-carbazole-1,4(9*H*)-dione(44), 6-fluoro-2-methyl-1*H*-carbazole-1,4(9*H*)-dione(45) and 6-fluoro-3-methyl-1*H*-carbazole-1,4(9*H*)-dione(46) have been studied against *Escherichia coli* (MTCC 42), *Bacillus subtilis* (MTCC 121), *Staphylococcus aureus* (MTCC 96), Methicillin-resistant *Staphylococcus aureus* (MRSA) and *Pseudomonas* sp. (MTCC 6199). The experimental results show that methyl substituent at C-2 and C-3 along with electron withdrawing fluorine atom at C-6 in the carbazoloquinone as well as the compound (42, 43, 45 and 46) showed antibacterial activity against MRSA.

Clausen J.D., et al (2017)⁴⁷ has synthesized a carbazole series have been identified as potent fungal plasma membrane proton

adenosine triphosphate (H⁺-ATPase) inhibitors with a broad spectrum of antifungal activity. The carbazole compound (47) inhibit the adenosine triphosphate (ATP) hydrolysis activity of the essential fungal H⁺-ATPase, thereby functionally inhibiting the extrusion of proton and extracellular acidification, processes that are responsible for maintaining high plasma membrane potential. The compound class binds to and inhibits the H⁺-ATPase within minutes, leading to fungal death after 1-3h of compound exposure *in vitro*. The tested compounds are not selective for fungal H⁺-ATPase, exhibiting an overlap of inhibitory activity with the mammalian protein family of p-type ATPase the sarcoendoplasmic reticulum calcium ATPase (CA²⁺-ATPase) and the sodium potassium ATPase (Na⁺ K⁺-ATPase). The ion transport in the p-type ATPases is energized by the conversion of ATP to adenosine diphosphate (ADP) and phosphate and a general inhibitory mechanism mediated by the carbazole derivative could therefore be blocking of the active site. However, biochemical studies show that increased concentration of ATP do not change the inhibitory activity of the carbazoles suggesting they act as allosteric inhibitors. Furthermore, decreased levels of intracellular ATP would suggest that the compounds inhibit the H⁺-ATPase indirectly, but *Candida albicans* cells exposed to potent H⁺-ATPase-inhibitory carbazoles result in increased levels of intracellular ATP, indicating direct inhibition of H⁺-ATPase.

Gluszynska Agata (2015)⁴⁸ has synthesized new macrocyclic diamides based on carbazole skeleton with thia and oxy-linkage system. Antimicrobial activities of compounds were tested against four human pathogenic bacteria such as *Proteus mirabilis*, *Proteus vulgaris*, *Staphylococcus aureus*, and *Salmonella typhi*. Antifungal activity of these compounds was also tested against four plants pathogenic fungi such as *Rhizoctonia solani*, *Macrophomina phaseolina*, *Curvularia lunata* and *Alternaria alternata*. The screening of amides compound (48 and 49) for their biological activity expressed by minimum inhibitory concentration (MIC), was performed *in vitro* conditions with the use of a control sample (10% DMSO) and commercial antibiotics, tetracycline and carbendazim (for plant pathogenic fungi).

The carbazolophanes (48) and (49) exhibited good antibacterial and antifungal activities against all pathogens.

Anti-mycobacterium activity

Surineni. G., et al (2018)⁴⁹ have been design, synthesis and evaluation of novel series of

dibenzofuran, dibenzothiophene and *N*-methyl carbazole tethered 2-aminothiazoles and their cinnamide analogs. 1-pot condensation of *N*-methyl carbazole, dibenzofuran and dibenzothiophene methyl ketone with thiourea in the presence of iodine and CuO gave respective 2-aminothiazoles 4-6 in a very good yield. Aminothiazoles were further coupled with substituted cinnamic acids using acid amine coupling conditions to give desired cinnamide analogs 50, 51. *In vitro* screening of new derivatives against *Mycobacterium tuberculosis*.

Shaikh. Mahamadhanif. S., et al (2014)⁵⁰ has synthesized various substituted carbazole-thiazoles(52a-o) by using a molecular hybridization approach. The synthesized compounds were evaluated for their *in vitro* anti-tubercular activity against *Mycobacterium tuberculosis* H₃₇Rv strain at the national Institute of Allergy and infectious diseases (Bethesda, MD, USA). Among the tested series, compound (52) (minimum inhibitory concentration 21 μM) showed the most promising anti-mycobacterial activity. Brief structure activity relationship studies showed that the electron donating groups (OCH₃ and OH), particularly on the phenyl ring of the thiazole motif, had a positive correlation with the anti-mycobacterial activity. In addition, they displayed low cytotoxicity against a mammalian vero cell line using the MTT assay, thereby having a high therapeutic index. This study shows the importance of molecular hybridization and the scope for the development of carbazole thiazole compounds as potential anti-mycobacterial agents.

Yogeeswari. P., et al (2014)⁵¹ has synthesized a series of novel carbazole tethered pyrrole(53a-i) derivatives were designed by coupling core fragments of antitubercular agents, carbazole and substituted pyrrole in single molecular architecture. The synthesized of new analogues was achieved by FeCl₃ mediated one pot three component condensation of 2-nitrovinylcarbazoles with aryl or alkyl amines and dimethylacetylenedicarboxylate (DMAD). All new synthesized compounds were screened for *in vitro* anti-mycobacterial activity against *Mycobacterium tuberculosis* H₃₇Rv, Dimethyl 1-(4-fluorophenyl)-4-(9-methyl-9H-carbazole-3-yl)-1 *H*-pyrrole-2,3-dicarboxylate (53) was found to be most active with MIC 3.13 μg/ml and has shown low cytotoxicity.

Antiproliferative activity

Sinicropi. S.M., et al (2017)⁵³ have been synthesized carbazole derivatives constitute an interesting class of heterocycles, which showed several pharmaceutical properties and

occupied a promising place as antitumor tools in preclinical studies. They target several cellular key-points, e.g. DNA and topoisomerase I and II. The most studied representative, i.e. ellipticine, was introduced in the treatment of metastatic breast cancer. However, because of the onset of dramatic side effects, its use was almost dismissed. Many efforts were made in order to design and synthesized new carbazole derivatives with good activity and reduced side effects. The major goal of the study was to synthesized a series of new *N*-thioalkylcarbazole derivatives with anti-proliferative effects. Compound (54) possess an interesting anti-proliferative against breast and uterine cancer cell lines without affecting non-tumoral cell lines viability. Wang.W., et al (2016)⁵⁴ have been synthesized novel carbazole amino-alcohols as anticancer agents. Among them alkylamine-chain-substituted compound (55) showed the most promising antiproliferative activity, with IC₅₀ values in the single-digit micromolar range against two human tumor cell lines. Topoisomerase I (topo I) is likely to be one of the targets of these compounds. Results of comet assays and molecular docking indicate that the representative compounds may act as topo I poisons causing single-strand DNA damage by stabilizing the topo I-DNA cleavage complex. In particular, the most potent compound, 1-(butylamino)-3-(3,6-dichloro-9-yl)propan-2-ol was shown to be able to induce G2 phase cell cycle arrest and apoptosis in HeLa cells.

Miscellaneous activity

Antidiabetic activity

Adib. M., et al (2019)⁵⁵ have synthesized twenty-three fused carbazole-imidazoles(56-w) and screened as new α-glucosidase inhibitors. All the synthesized fused carbazole-imidazoles were found to be more active than acarbose (IC₅₀=750.0 ± 1.5 μM) against yeast α-glucosidase with IC₅₀ in the range of 74.0 ± 0.7-298.3 ± 0.9 μM. kinetic study of the most potent compound demonstrated that this compound is a competitive inhibitor for α-glucosidase (K_i value=75 μM). Furthermore, the *in-silico* studies of the most potent compounds (56o) and (56v) confirmed that these compounds interacted with the key residues in the active site of α-glucosidase

Antimalarial activity

Kandor V.A., et al (2019)⁵⁶ have been synthesized a series of carbazole based 1,4-benzothiazepine and pyrazoline(57a-f) derivatives were synthesized and the structures of the newly synthesized compounds were confirmed by FT-IR, 1H

NMR, ¹³C-NMR and mass spectral studies. All new derivatives were screened for their *in vitro* antimalarial activity. Compound (57a, 57b and 57d) exhibited promising antimalarial activity.

Antioxidative activity

Dabrovoliskas K., et al (2020)⁵⁷ several compounds were synthesized and evaluated antioxidative activity using free 1,1-diphenyl-2-picryl-hydrazyl radical scavenging assay and ferric reducing antioxidant power methods. Compound (58) was most potent.



Antiviral

Caruso. A., et al (2019) have synthesized a series of carbazole derivatives. Reported the Viruses represents the most common cause of infectious disease worldwide and those with rapid propagation high infection rates cause human and animal pandemics. The fast-spreading diseases are generally treated with antiviral drugs but, often, drug resistance occurs because of the ability of the pathogens to mutate rapidly and become less susceptible to the treatments. Even though new antiviral compound (59) has been affected, e.g., in HIV (human immunodeficiency virus) HCV (hepatitis C virus) therapeutic areas, the need of dispose of new pharmaceutical tools for the management of infections that still have no

treatment is growing interest. In these areas, carbazole represents an important privileged scaffold in drug discovery. Many compounds with a carbazolic core have been developed and some of them have shown antiviral activity. This review provides an overview on some already known carbazole derivatives, pointing the attention on the running progresses in identifying new molecules with carbazolic structure, that have shown interesting and encouraging *in vitro* and *in vivo* properties. These drugs may be exploited as valid alternatives in antiviral therapy.


CONCLUSION

In recent 10 years, numerous carbazole derivatives have been synthesized and subjected to studies with various biological activities. Some of carbazole compounds have a very high activity against many organisms: bacteria, fungi, parasites, or are potential anti-inflammatory agents. The antimicrobial and antifungal activities of different compounds, including macrocyclic diamides and azoles based on carbazole skeleton, have been tested against many human pathogenic bacteria and fungi. Some of the compounds showed comparable or even better antibacterial and antifungal properties against tested strains than the reference drugs.




(1) (2)

NR₁N₂=Quinoline




(3)


X=Cl, y=H, Z=H, Z'=Cl









(4)




(5)




(6)




R=(a) p-OCH₃, (e) p-Br, (g) 2,6-DiCH₃, (h) p-CH₃




(13)



(14)




(15)




(16)


R= (a) *p*-nitro, (d) *p*-chloro, (e) *p*-(dimethylamino),
(n) *p*-Flouro



(17)




(18)




(19)

19b=2,4-dimethoxyphenyl, 19c=2,3-dimethoxyphenyl, 19f=pyridine-4-yl, 19g=pyrrol-2-yl




R- a=2-f,4-Br, b= 4-NO₂ g= 4-CN


(20)




NR₁,R₂ =




(21)




R₁R₂ -



(22)




(23)




R= 4-dimethylamino

(24)




R= 4-dihydroxy


(25)



X=N-Me, Y=




(26)




Ar= 5-Hydroxyphenyl


(27)




R₁ = CH₃, R₂ = H
(28)




(29)




X = Br
(30)










- (31) $R_1=OH, R_2=NHCH_2CH_2OH$
 (32) $R_1=OMe, R_2=CH_2NHCCH_2CH_3(CH_2OH)$
 (33) $R_1=OH, R_2=NHC(CH_3)_2CH_2OH$




- (34a) Ar= 2-Methylphenyl
 (34c) Ar=4-Ethylphenyl
 (34e) Ar= 4-chlorophenyl
 (34j) Ar=3,4-Diethylphenyl
 (34i) Ar=3,5-Dimethylphenyl




- (35)
 (35A) $R^1=Hydrogen, R^2=Thiophene-2-ethyl$
 (35b) $R^1=Hydrogen, R^2=Prop-2-yl$
 (35c) $R^1=1-(Morpholinyl)$







(42)




(43)




(44)







(45)




(46)




(47)







52C= R=3,4-OCH₃
(52)




(53)


R= CH₃, R₁=




R₁=R₂= CH₃, R₃=Br
(54)







X=Cl, X=




(55)




Ar



(56)




(57)



(58)

57a= R₁=Cl, R₂=H, R₃=Cl
 57b= R₁=Cl, R₂=H, R₃=H
 57d= R₁=Br, R₂=H, R₃=H



REFERENCES

- Beliers M, Sartor V, Fabre PL, Poteau R, Bordeau G and Lalanne NC. Simple electron donar molecules based on triphenylamine and carbazole derivatives. *Dyes and Pigments*. 2018; 153:275-283.
- Bashir M, Bano A, Ijaz AS and Chaudhary BA. Recent developments and biological activities of N-substituted carbazole derivatives: A Review. *Molecules*. 2015;20:13496-13517.
- Kaplancikli ZA. Synthesis of some novel carbazole derivatives and evaluation of their antimicrobial activity. *Pharma J*. 2011;15:105-109.
- Kaushik K, kumar N and Pathak D. Docking, synthesis and anticancer activity of some newer carbazole derivatives. *International J. of pharma. Chem*. 2012;4:470-478.
- Kadam ML, Patil D and Sekar N. Fluorescent carbazole based pyridine dyes-synthesis, solvatochromism, linear and non linear optical properties. *Optical Material*. 2018;85:308-3018.
- Bashir M, Bano A, Ijaz AS and Chaudhary BA. Recent developments and biological activities of N-substituted carbazole derivatives: A Review *Molecules*. 2015;20:13496-13517.
- Zhang FF, Gen LL and Zhou CH. Synthesis, antibacterial and antifungal activities of some carbazole derivatives. *Bioorg. Med Chem Lett*. 2010;20:1881-18884.
- Balouiri M, Sadiki M and Ibensouda SK. Methods for in vitro evaluating antimicrobial activity: A review. *J. of Pharm. Analysis*. 2016;6:71-79.
- Ryan A, Tuffy B, Horn S, Blau WJ and Senge MO. *Tetrahedron*. 2011;67:8348-8254.
- Rice NA and Adronov A. *Macromolecules*. 2013;46:3850-3860.
- Won C and Lee JY. *Dyes pigments*. 2014;103:34-38.
- Songsiang U, Thongthoom T, Boonyarat C and Yenjai C. *Nat Prod*. 2011;74:208-212.
- Ma Q, Tian J, Yang A, Wang T Ji, Wang Y and Su Y. *Fitoterapia*. 2013;87:1-6.
- Mahapatra DK, Bharti SK and Asati V. *Eur J Med Chem*. 2015;98:69-114.
- Saravanabhavan M, Sathya VG, Puranik M and Sekar. *Spectochim Acta A Mol. Biomol Spectrosc*. 2014;118:399-406.
- Molette J, Routier J, Alba N, Besson D, Bombrun A, Brun R, Burt H, Georgi K, Kaiser M, Nwaka S, Muzerelle M and Scheer A. *ACS Med. Chem Lett*. 2013;4:1037-1041.
- Bandgar BP, Adsul LK, Chavan HV, Jalde SS, Shringare S, Shaikh R, Meshram RJ, Gacche RN and Masand V. *Bioorg Med Chem Lett*. 2012;22:5839-5844.
- Zall A, Kieser D, Hottecke N, Naumann EC, Thomaszewski B, Schneider K, Steinbacher DT, Schubanel R, Masur S, Baumann K and Schmidt B. *Bioorg Med Chem*. 2011;19:4903-4909.
- Thiratmatrakul S, Yenjai C, Waiwut P, Vajragupta O, Reubroycharoen P, Tohda M and Boonyarat C. *Eur J Med Chem*. 2014;75:21-23.
- Macmillan KS, Naidoo J, Liang J, Melito L, Williams NS, Morlock L, Huntington PJ, Estill SJ, Longgood J, Becker GL, Mcknight SL, Piper AA, Brabander JK and Ready JM. *J Am Chem Soc*. 2011;133:1428-1437.
- Choubdar N, Golshani M, Baleh L, Nadri H, Kucukkilinc T, Ayazgok B, Moradi A, Moghdadam FH, Abdolahi Z, Aeri A, Salehian F, Foroumadi A and Khoobi M. New class of carbazoles as potential multi-functional anti-Alzheimer's agents. *Bioorg Med Chem*. 2019;91:1-10.

22. Ghobadian R, Nadri H, Moradi A, Bukhari SNA, Mahadevi M, Asadi M, Akbarzadeh, T, Sharifzadeh M and Amini M. Design, synthesis and biological evaluation of selective and potent carbazole-based butyrylcholinesterase inhibitors. *Bioorg med Chem.* 2018;8:1-26.
23. Dabrovoliskas K, Jonuskiene I, Sutkuvienė S and Gudeika D. Synthesis and evaluation of antibacterial and antioxidative activities of carbazole derivatives. *Chemija.* 2020;31:42-51.
24. Venkatapathy K, Magesh CJ, Lavanya G, Perumal PT and Prema S. Design, synthesis, molecular docking, and spectral studies of new class of carbazolylpolyhydroquinoline derivatives as promising antibacterial agents with noncytotoxicity towards human mononuclear cells from peripheral blood. *J. Heterocyclic Chem.* 2020;57:1-20.
25. Guhanathan S, Murugesan MS and Sangeetha U. Investigation of dibromo and N-bromoacetyl derivatives of [b] carbazole-synthesis and antibacterial evaluation. *International J of New Chem.* 2019;6:66-75.
26. Pattanashetty SH, Hosamani KM, Shettar AK and Shafeeulla RM. Design, synthesis and computational studies of novel carbazole N-phenylacetamide hybrid as potent antibacterial, anti-inflammatory, and antioxidant agents. *J Heterocyclic Chem.* 2018.
27. Wang PY, Fang HS, Shao WB, Zhou J, Chen Z, Song BA and Yang S. synthesis and biological evaluation of pyridinium-functionalized carbazole derivatives as promising antibacterial agents. *Bioorg. Med. Chem. Lett.* 2017; 27: 4294-4297.
28. Parthiban P, Alagarsamy V, Narayanan BL, Babu P, Singh Hanish JC, Design, synthesis antibacterial and antifungal activity of some substituted tetrahydro carbazole derivatives. *International J. of pharmacy and pharmaceutical Analysis.* 2014;01:1-8.
29. Sharma D, Kumar N and Pathak D. Synthesis, characterization and biological evaluation of some newer carbazole derivatives. *J of the Serbian Chemical Society.* 2014;79:125-132.
30. Kaushik K, Kumar N and Pathak D. Synthesis of some newer carbazole derivatives and evaluation for their pharmacological activity. *Pelagia Research Library.* 2012;3:470-478.
31. Liu Y, Wu Y, Sun L, Gu Y and Hu L. Synthesis and structure-Activity relationship study of water-soluble carbazole sulfonamide derivatives as new anticancer agents. *Eur J of Med Chemistry.* 2020;191:1-41.
32. Rao BVD, Sreenivasulu R and Rao MVB. Design, synthesis and evaluation of isoxazole-Thiadiazole linked carbazole hybrids as anticancer agents. *Russian J of General Chem.* 2019; 89:2115-2120.
33. Jing H, Zhang WJ, Li PH, Wang J, Dong CH, Zhang K, Chen HX and Du ZY. Synthesis and biological evaluation of novel carbazole-rhodanine conjugates as topoisomerase II inhibitors. *Bioorg Med Chem Lett.* 2018;28:1320-1323.
34. Vlaar CP, Pichardo LC, Medina JI, Velez E, Ramos Z and Hernandez E. Design, synthesis and biological evaluation of new carbazole derivatives as anti-cancer and anti-migratory agents. *Bioorg Med Chem.* 2018;26:884-890.
35. You X, Zhu D, Lu W, Sun Y, Qiao S, Luo B, Du Y, Pi R, Hu Y, Huang P and Wen S. Design, synthesis and biological of N-arylsulfonylcarbazoles as novel anticancer agents. *Royal society chem.* 2018;8:17183-17190.
36. Kumar N and Pathak D. Design, synthesis and anticancer activity of 9-substituted carbazole derivatives. *International J. pharma science and research.* 2016;8:3291-3298.
37. Li B, Yue Z, Feng J, He Q, Miao ZH and Yang CH. Design and synthesis of pyrido[3,2- α] carbazole derivatives and their analogues as potent antitumor agents. *European J med Chemistry.* 2013;66:531-539.
38. Gu W, Hao Y, Zhang G, Wang SF, Miao TT and Zhang KP. Synthesis, in vitro antimicrobial and cytotoxic activities of new carbazole derivatives of ursolic acid. *Bioorg med Chem Lett.* 2015;25:554-557.
39. Haider N, Marian B, Nagel T, Tarnai M and Tropper K. Electrophilic substitution of Dimethyl 1-Methylcarbazole-2,3-dicarboxylate: Synthesis of new b-Fused carbazoles as potential antitumor agents. *J Braz Chem Soc.* 2014;25:1965-1974.
40. Howorko RJ, Tylinska B, Biadun B, Gebarowski T and Gasiowski K. Synthesis of new pyridocarbazole

- derivatives their in vitro anticancer activity. *Acta Poloniae Pharmaceutica*. 2013;70:823-832.
41. Kaplancikli ZA, Yurttas L, Zitouni GT, Ozdemir A, Ozic R and Yildirim SU. Synthesis, antimicrobial activity and cytotoxicity of some new carbazole derivatives. *J enzyme inhibition med Chem*. 2012;27:868-874.
 42. Muniyappan G, Kathvarayan S, Kella CR, Kalliyappan E, Ponnusamy S and Thirumalai P. Synthesis of novel 4-hydroxycarbazole derivatives and evaluation of their in vitro anti-inflammatory, antioxidant activities and molecular docking. *Research on Chem. Intermediates*. 2016;43:1-17.
 43. Surendiran T. Studies on anti-inflammatory behaviour of chalconyl, isoxazoliny and pyrazoliny 1,2,3,4-tetrahydrocarbazoles. *international J. pharma tech research*. 2018;8:183-188.
 44. Bandgar BP, Adsul LK, Chavan HV, Jalde SS, Shringar SN, Shaikh R, Meshram RJ, Gacche RN and Masand V. Synthesis, biological evaluation, and docking studies of 3-(substituted)-aryl-5-(9-methyl-3-carbazole)-H-2-pyrazolines as potent anti-inflammatory and antioxidant agents. *Bioorg Med Chem Lett*. 2012;22:5839-5844.
 45. Jasass RS, Alshehrei F and Farghaly TA. Microwave- Assisted Synthesis of Antimicrobial agents containing carbazole and thiazole moieties. *J. Hetrocyclic Chem*. 2018;55:1-8.
 46. Chakraborty S, Saha A, Saha C, Ghosh TK and Bhattacharyya I. Evaluation of antimicrobial activity of synthesized fluorocarbazole derivatives based on SAR. *Indian J of chem*. 2017; 56B:701-708.
 47. Clausin JD, Kjellerup L, Cohrt KO, Hansan JB, Brown WD and Winther AM. Eluciation of antimicrobial activity and mechanism of action by N-substituted carbazole derivatives. *Bioorg Med Chem Lett*. 2017;27:4564-4570.
 48. Gluszynsk A. Biological potential of carbazole derivatives. *European J med Chem*. 2015;91: 405-426.
 49. Surinei G, Marvadi SK, Yogeewari PS, Sriram D and Kantevari. Dibenzofuran, dibenzothiophene and N-methyl carbazole tethered 2-aminothiazoles and their cinnamamides as potent inhibitors of mycobacterium tuberculosis. *Bioorg Med chem Lett*. 2018;28:1610-1614.
 50. Shaikh MS, Palkar MB, Patel HM, Rane R, Alwan W, Shaikh M, Hampannavar G and Karpoomath R. Design and synthesis of novel carbazolo-thiazoles as potential anti-mycobacterial agents using a molecular hybridization approach. *Royal soceitychem*. 2014;4: 62308-62320.
 51. Surinei G, Marvadi SK, Yogeewari P, Sriram D and Kantevari. Design and synthesis of novel carbazole tethered pyrrole derivatives as potent inhibitors of mycobacterium tuberculosis. *Bioorg Med chem Lett*. 2015;25:485-491.
 52. Sinicropi MS, Lacopetta D, Rosano C, Randino R, Caruso A, Saturnino C, Muia N, Ceramella J, Puoci F, Rodriquez M and Plutino. N-thioalkylcarbazoles derivatives as new anti-proliferative agents: synthesis, characterization and molecular mechanism evaluation. *J enzyme Inh Med Chem*. 2018;33:434-444.
 53. Wang W, Sun X, Sun D, Li S, Yu Y, Yang T, Yao J, Chen Z and Duan L. Carbazoleaminoalcohols induce antiproliferation and apoptosis of human tumor cells by inhibiting topoisomerase I. *Chemical med chem*. 2016;11:1-8.
 54. Adib M, Peytam F, Shourgeshty R, Khanaposhtani M, Jahani M, Imanparast S, Faramarzi MA, Larijani B, Moghadamnia AA, Esfahani EN, Bandarian F and Mahdavi M. Design and synthesis of new fused carbazole-imidazole derivatives as anti-diabetic agents: In vitro α -glucosidase inhibition, kinetic, and in silico studies. *Bioorg Med Chem Let*. 2019;29:713-718.
 55. Shelke SN and Kadnor VA. Synthesis, antimalarial activity of 1,4-benzothiazepine and pyrazoline derivatives incorporating carbazole moiety. *Bulgarian chemical communications*. 2019;51:234-241.
 56. Dabrovolskas K, Jonuskiene I, Sutkuvienė S and Gudeika D. Synthesis and evaluation of antibacterial and antioxidative activities of carbazole derivatives. *CHEMIJA*. 2020;31:42-51.
 57. Caruso A, Ceramelle J, Lacoppta D, Saturnino C, Mauro MV, Bruno R, Aquaro S and Sinicropi MS. Carbazole derivatives as antiviral agents: An overview. *Molecules*. 2016;24:1-23.